Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Taneja

Showing results (291-300 of 845) with videos related to

Pageof 85
Sort By:
The Journal of Urology|February 14, 2014
Re: aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialSamir S Taneja
The Journal of Urology|February 14, 2014
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialSamir S Taneja
The Journal of Urology|November 11, 2018
Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerSamir S Taneja
The Journal of Urology|February 18, 2017
Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active SurveillanceSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate CancerSamir S Taneja
The Journal of Urology|January 18, 2017
Re: Magnetic Resonance Imaging-Ultrasound Fusion Biopsy during Prostate Cancer Active SurveillanceSamir S Taneja
The Journal of Urology|July 12, 2019
Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerSamir S Taneja
The Journal of Urology|July 12, 2019
Re: Apalutamide for Metastatic, Castration-Sensitive Prostate CancerSamir S Taneja
The Journal of Urology|April 16, 2020
Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate CancerSamir S Taneja
The Journal of Urology|April 20, 2015
Re: Does discontinuous involvement of a prostatic needle biopsy core by adenocarcinoma correlate with a large tumor focus at radical prostatectomy?Samir S Taneja
Pageof 85

Showing results (291-300 of 845) with videos related to

Sort By:
Pageof 85
The Journal of Urology|February 14, 2014
Re: aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialSamir S Taneja
The Journal of Urology|February 14, 2014
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialSamir S Taneja
The Journal of Urology|November 11, 2018
Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerSamir S Taneja
The Journal of Urology|February 18, 2017
Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active SurveillanceSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate CancerSamir S Taneja
The Journal of Urology|January 18, 2017
Re: Magnetic Resonance Imaging-Ultrasound Fusion Biopsy during Prostate Cancer Active SurveillanceSamir S Taneja
The Journal of Urology|July 12, 2019
Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerSamir S Taneja
The Journal of Urology|July 12, 2019
Re: Apalutamide for Metastatic, Castration-Sensitive Prostate CancerSamir S Taneja
The Journal of Urology|April 16, 2020
Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate CancerSamir S Taneja
The Journal of Urology|April 20, 2015
Re: Does discontinuous involvement of a prostatic needle biopsy core by adenocarcinoma correlate with a large tumor focus at radical prostatectomy?Samir S Taneja
Pageof 85